Check for updates

METHOD ARTICLE

Multi-parametric characterization of drug effects on cells

[version 1; peer review: 2 approved]Yael Paran ^{1,2}, Yuval Liron¹, Sarit Batsir¹, Nicola Mabjeesh ³, Benjamin Geiger ^{1,4}, Zvi Kam ¹¹Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, 76100, Israel²IDEA Biomedical Ltd., Rehovot, 76705, Israel³Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel⁴Department of Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel**V1** First published: 05 Oct 2020, 9(ISF):1199
<https://doi.org/10.12688/f1000research.26254.1>Latest published: 21 Jan 2021, 9(ISF):1199
<https://doi.org/10.12688/f1000research.26254.2>**Abstract**

We present here a novel multi-parametric approach for the characterization of multiple cellular features, using images acquired by high-throughput and high-definition light microscopy. We specifically used this approach for deep and unbiased analysis of the effects of a drug library on five cultured cell lines. The presented method enables the acquisition and analysis of millions of images, of treated and control cells, followed by an automated identification of drugs inducing strong responses, evaluating the median effect concentrations and those cellular properties that are most highly affected by the drug. The tools described here provide standardized quantification of multiple attributes for systems level dissection of complex functions in normal and diseased cells, using multiple perturbations. Such analysis of cells, derived from pathological samples, may help in the diagnosis and follow-up of treatment in patients.

Keywords

Microscope imaging, Multiparameter scoring, Drug effect screening

Open Peer Review**Approval Status**

1

2

version 2

(revision)

21 Jan 2021

version 1

05 Oct 2020

[view](#) [view](#)1. **John Lock** , University of New South Wales, Sydney, Australia2. **Robert Murphy** , Carnegie Mellon University, Pittsburgh, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Zvi Kam (kamrachel@gmail.com)

Author roles: **Paran Y:** Data Curation, Formal Analysis, Investigation, Project Administration, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Liron Y:** Formal Analysis, Methodology, Software; **Batsir S:** Formal Analysis, Validation, Visualization; **Mabjeesh N:** Conceptualization, Funding Acquisition, Methodology, Resources; **Geiger B:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kam Z:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: B.G. holds the E. Neter chair in Cell and Tumor Biology, Z.K. is the Israel Pollak Professor of Biophysics.

Grant information: The research reported here is supported by grants from the Kahn Family Foundation for Systems Biology of the Human Cell at the Weizmann Institute of Science (Z.K.), Weizmann-Sourasky collaboration grant funded by the M.D. Moross Institute for Cancer Research (N.M. and Z.K.) and Yad Abraham Center for Cancer Diagnosis and Therapy.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Paran Y *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Paran Y, Liron Y, Batsir S *et al.* **Multi-parametric characterization of drug effects on cells [version 1; peer review: 2 approved]** F1000Research 2020, 9(ISF):1199 <https://doi.org/10.12688/f1000research.26254.1>

First published: 05 Oct 2020, 9(ISF):1199 <https://doi.org/10.12688/f1000research.26254.1>

Introduction

Advanced precision medicine enables the use of genetic and proteomic information for the characterization of disease states, based on the correlation with detailed medical records and specific pathological manifestations^{1–11}. Indeed, multi-component “omics” profiling can report a large number of components of the genome, transcriptome, proteome, interactome and metabolome (to name a few), and detect even a small fraction of them, indicating significant changes from normal^{12–16}, yet this fraction may not fully overlap with the currently used repertoire of medical manifestations in complex diseases such as heterogeneous cancers^{17–26}. We address here the possibility of using multi-parametric characterizations of cellular features for identifying novel signatures of functional cell states, and offer quantitative diagnostic, as well as mechanistic measures, of disease progression or suppression following therapy.

It is widely recognized that meaningful understanding of disease states needs to be achieved in the context of the whole body physiology and tissue functional morphology, yet cell-level functional abnormalities lie at the basis of many pathologies, and may thus be identified by recordable cellular attributes. Developments in quantitative light microscopy, either in two-dimensional or in three-dimensional model settings, has been combined with live cell microscopy and recent adaptation of microfluidics technologies to screening and personalized treatment optimization with primary cells, spheroids, organoids and tissue biopsies^{27–33}. The difficulty in quantitative characterization of multiple cellular features of biological specimens with diverse morphological and molecular properties creates an urgent need for methodologies that can be standardized, yield strong statistical scores and can be automated for effective application in systems-level biomedicine.

The value of multi-parametric analysis is well recognized in flow cytometry³⁴, and is mandatory when the strategies aiming at functional screening depart from cell reporters for specific drug-target interactions. The application of multi-parametric analysis to cell screening has become a common place. Perlman *et al.*^{35,36} have designed a titration-invariant similarity score (TISS) based on multi-parametric dose response matrix for each drug, allowing comparison of drug effects to reflect similarity of mechanisms of action. Classification of patterns displayed by tagged proteins in cells^{37–43} is a powerful way to sort sub-cellular localizations, but is bound to cellular responses reflected by the labeled epitopes (e.g. nucleus vs. cytoplasm localization). Tanaka *et al.*⁴⁴ based their analysis on multi-parameter evaluations, using Principal Components Analysis (PCA) to reduce the number of independent parameters so that the multi-dimensional state vectors of cells treated with drugs could be displayed in 3D plots to differentiate or correlate effects and infer similar mechanisms. Melnick *et al.*⁴⁵ obtained their multi-parametric data vectors from 35 tyrosine-kinase-activated cellular assays responding to 1400 kinase inhibitors, and used clustering in Euclidian space to sort perturbations similar in action to known drugs. Screens have also been developed to dissect cellular mechanisms^{42,46} and identify proteins involved in cellular processes using interference RNA perturbations^{43,47}. Rather than prior definition of the type of effect (e.g. cell death) or a marker to a specific

function, the analysis developed here quantifies drug effects on cell phenotypic and molecular attributes in high dimensionality space.

In this study we have determined the effects of the NCI COMBO drug collection [48, Plate number 3948] on five cell lines; the well-established cervical carcinoma-derived HeLa cells and four cell lines derived from bladder cancers⁴⁹, and used light microscopy-based screening to record multiple cellular responses to the tested drugs. Parameters such as total protein levels, cytoplasmic-nuclear distributions and cell death were analyzed at low magnifications (X10/0.25 objectives)⁵⁰, while high-definition imaging, providing detailed intracellular data about fine protein localization (e.g. cytoskeletal fibers, sub-cellular organelle morphology, etc.) used higher power objectives (60x/0.95), providing multi-dimensional information needed to link drug responses with molecular mechanisms and cellular functions.

In order to be able to read properties of cells and measure as many aspects of system-level response to the treatments, we developed an analysis platform for multi-parametric characterization of cellular features and unbiased scores, based on Mahalanobis distances, for identifying the potency of drugs producing a wide variety of effects. The multi-parametric score is a single value representing the difference from control cells, that contain, however, the complete information on the individual contributions of each of the measured parameters, enabling us to identify those that are mostly affected by each perturbation. Furthermore, the score allows quantification of time-dependencies, examination of cell-line differential responses, and prediction of expected synergy of drug combinations.

Methods

Cells

HeLa, and four cell lines derived from bladder cancers (UMUC3, TCCSUP, HT1376 and RT4¹) were obtained from the ATCC. Cell lines were maintained in DMEM supplemented with 10% FBS (Sigma-Aldrich, Rehovot, Israel) and penicillin/streptomycin antibiotics. Cells were grown in polystyrene petri dishes.

Drugs

Drugs were obtained from the National Cancer Institute (NCI). The COMBO plate number 3948⁴⁸ includes 77 compounds, 23 of which are FDA-approved anti-cancer drugs. Mechanisms of action include anti-metabolite activity, tubulin binding, DNA damage, Hsp90 binding, as well as inhibition of topoisomerases, kinases, the proteasome, angiogenesis, ion channels, palmitoylation, phosphodiesterase, cyclooxygenase, and aromatase.

Sample preparation

Cells were suspended and transferred to 384 well plates (thin plastic bottom, Cat #781091 Greiner-Bio One, D-72636

¹RT4 cells were received to the lab in November 2006 from the ATCC. RT4 cells are much smaller than HeLa and have different morphology. We could clearly see that there was no HeLa contamination in our RT4 cells.

Frickenhausen) using BioMek FX liquid handling robot (Beckman Coulter, Fullerton, CA 92834) at a density of 1000 cells/well and cultured for one day. Drugs were then added at the ten three-fold dilutions, concentration range: $(10 \times 10^{-4}) \times GI_{50}$, (GI_{50} is the concentration of the least sensitive line in the NCI60, see *Extended data: Table S1*⁵¹). Following the specified incubation time with the drugs, cells were fixed, labeled with DAPI for nuclei (Life, Molecular Probes D1306), FITC-Phalloidin for F-Actin (Life, Molecular Probes F432) and indirectly immunolabeled for tubulin (Primary Antitubulin antibodies (SIGMA T6199)) and Cy3-labeled secondary antibodies (Alexa Fluor546 –Life, Molecular Probes A11030), and washed by the robot. For drug effect measurement, ten 3-fold dilutions in duplicates were arranged in plate rows, starting from 50 times the median effect concentration specified for the COMBO collection. The transfer order and

concentrations from the 96-well COMBO drugs plate into six 384-well plates for each of the 5 cell lines are listed in *Extended data: Table S1*⁵¹.

A total of 16 binary combinations were selected from 20 drugs that showed cellular effects. Matrices with two-fold dilutions in duplicate with drug concentrations up and down from the median effect concentrations, as listed in *Table 1*, were prepared for two cell lines (TCCSUP & UMUC3). Four such matrices were arranged in one 384-well plate, and rearranged for presentation, including duplicate averaging, as “virtual plates”.

Imaging

Plate scanning and multi-color image acquisition was performed by WiScan Argus (Idea-biomedical, Rehovot 76705, Israel; <https://idea-bio.com>) a fast, high-resolution screening

Table 1. List of drugs that induced cellular responses. Median-effect values were fitted to the scores in *Figure 1* using the equation in the Methods. The table lists D_m , the column number of half effect for the drug rows marked by arrows in *Figure 1*. The higher the D_m number is, the more effective the drug is at higher dilutions. The corresponding concentration for a specific drug is $10 \times GI_{50} \times 3^{(1-D_m/2)}$ (3-fold dilutions in duplicates from initial 50 fold dilution of the COMBO supplied concentration, set as 500 times the drug GI_{50}).

Plate [row]	Drug name	HeLa	TCCSUP	UMUC3	HT1376	RT4
1 [I]	Curcubitacin	7	8	6	-	1
2 [E]	Angiogenesis***	-	1	5	1	-
3 [B]	Miconazole	-	4	5	2	-
3 [E]	Tetrandrine	-	4	2	-	-
3 [J]	Pimozide	-	3	3	-	-
3 [K]	Helenaalin	-	9	9	-	-
3 [O]	Curcumin	-	2	4	-	-
4 [H]	Radicinin	4	6	6	5	2
4 [I]	Methdilazine	3	4	4	3	1
4 [M]	Perezone	-	4	8	2	2
4 [O]	Ursolic acid	4	3	4	2	1
5 [G]	Celecoxib	-	3	2	1	-
5 [J]	Rhizoxin	1	2	2	3	2
5 [K]	Brasilin	-	4	5	2	-
5 [L]	Maytansine	-	4	6	2	-
5 [M]	BCNU	2	3	6	-	-
6 [B]	Colchicine	-	4	4	2	2
6 [F]	Vincristine sulfate	-	3	4	-	-
6 [G]	Valinomycin	-	-	2	-	-
6 [L]	Nocodazole	9	11	12	7	1
6 [M]	Paclitaxel (Taxol)	-	1	4	-	-

microscope system⁵²⁻⁵⁴. Images were stored locally during the screen, and transferred to 60 TeraBytes storage [NetApp, Sunnyvale, CA 94089] accessible to the analysis workstations via fast local Ethernet for visualization of raw images, interactive optimization of the analysis strategy and tuning of user-controlled parameters (see below). The automated analysis pipeline was then run, accumulating analyzed results to a data base, allowing results display and interpretation.

Analysis pipeline

In order to process the images, we used a computer cluster (Sun Microsystems), consisting of AMD dual-core computer nodes running Linux RedHat. The software used was WiSoft Minerva (Idea-biomedical).

The analysis scripts pipeline (*Extended data*⁵⁵; scripts can be used with any software) combines throughput with modularity. Analysis of different specimens and diverse assays requires a wide range of alternative algorithms and interactive capability to select between them and optimize user-defined parameters before processing the whole data. To achieve such flexibility, we broke the analysis into modular steps categorized by their functionality (Pre-processing, Segmentation and Quantification see *Extended data*: Figure S1⁵¹). Sequences of the analysis modules can be integrated like in a jigsaw puzzle and looped in cycle on all images acquired in an experiment. While such modular structure typically compromises performance, we implemented fast communication of images and data between modules via Shared Memory, achieving processing time as fast as would have been the processing time of an integrated optimized program. Every image is annotated during the acquisition (time, fluorescent color or transmitted light, position inside well, well in plate, plate in whole experiment), and the analyzed data carries these annotations, keeping track of the experimental organization (metadata). Calculation and display of statistics of the analyzed results is therefore directly linked with the experimental design structure. The “Plate GUI” is used to display plate-wide scores, and to interactively show (by a mouse click on a well) the original images and the corresponding numerical and statistical analyzed data. The access to all levels of the data is necessary for rational mining of the TeraBytes of digital information at all levels: original images, montages of image tiles, segmented objects, quantified parameters and statistical profiles. The scoring algorithm used here is based on Mahalanobis distances in multi-parametric space (see *Extended data*: Figure S2⁵¹). The attributes calculated for each cell are listed in *Extended data*: Table S2⁵¹.

Drug combination effect analysis

Combination matrix scores were fitted using Loewe-additivity and Bliss-independence models⁵⁶⁻⁵⁸ using the following steps:

- I. Fitting D_m and s in Chou’s medial effect equation to the single-drug response curve (first rows and columns in the combination matrices):

$$Af+B=A/[1+(D_m/D)^s]+B$$

where:

- f the fractional effect, here from the Mahalanobis score,
- $A+B$ the measured score amplitude at infinite drug concentration,
- B the score baseline at zero drug concentration.
- D_m the median effect concentration of the drug
- s the Hill parameter

The parameters A, B were first evaluated from the scores response curve minimum and maximum, D_m and s were obtained from the linearized equation for the log of normalized fractional effect data: $\log(1/f-1)=s*\log(D_m/D)$

The four parameters A, B, D_m, s were then used as initial estimates for a non-linear Marquet-Levenberg fit.

- II. Using the parameters $s_{1,2}$ for each of the two drugs to “span” the combination effect matrix, f_{comb} , as a function of the two concentrations, $D_{1,2}$, and solving f_{comb} from Loewe additivity equation:

$$D_1/[f_{comb}/(1-f_{comb})^{1/s_1}] + D_2/[f_{comb}/(1-f_{comb})^{1/s_2}] = 1$$

- III. Using the medial effect parameters $D_{m1,2}, s_{1,2}$ for each of the two drugs to “span” the combination effect matrix, f_{comb} , assuming Bliss independence:

$$f_{comb} = f_1 * f_2 = 1/[1+(D_{m1}/D_1)^{s_1}] / [1+(D_{m2}/D_2)^{s_2}]$$

- IV. Fitting the four parameters $D_{m1,2}, s_{1,2}$ using all the values in the combination matrix simultaneously, based on Loewe or Bliss models.

Results

Five established cell lines; four derived from urinary-bladder cancers, and one from cervical carcinoma, were plated in 384-well plates at a density of 1000 cells per well. Following incubation for 24h, the cells were treated with serial dilutions of the COMBO plate drugs⁴⁸ (ten, three-fold dilutions, concentration range: $(10-5 \times 10^{-4}) * GI_{50}$, where GI_{50} is the concentration of the least sensitive line in the NCI60, see *Extended data*: Table S1⁵¹) and further incubated for 18h (see Methods). The cells were then fixed and labeled (see Methods). Images were acquired in these three fluorescent channels (see top panels, Figure 1), and analyzed as described in the Methods and in *Extended data*: Figure S1⁵¹. The analysis yielded, for each well, a list of segmented cells, each characterized by a “vector” of quantified features (‘attributes’).

Whole cell segmentation was commonly achieved by diffuse cytoplasmic staining (e.g. “cell mask”, Invitrogen), with enhanced nuclear concentration. Cytoplasmic fluorescence (due to the monomer fraction of tubulin and actin and even cell autofluorescence) plus the definition of the nucleus by DAPI

Figure 1. Cell imaging and multi-parameter analysis. Five cell lines were cultured each in six 384 plates treated with concentration-dilution series of the COMBO drug plate (see Table 1 for drug order, each plate row is a dilution series in duplicates). Cells were imaged in three fluorescent colors (Red: Actin, Green: Tubulin & Blue: Nucleus, See image examples in top panels). Individual cells were segmented, and for each cell an array of attributes was quantified. Attributes include cells and nuclei morphological and fluorescence intensities attributes and microtubules and actin fiber attributes (see Methods and *Extended data*: Table S2). Color coded Mahalanobis Scores (see *Extended data*: Figure S2) are presented here for each well in six plates for the five cell lines. A number of drugs with strong cellular effects are displayed (red rows), and indicate some cell-line dependence. Robot error effects were minimized in the analysis by rejecting outliers lying outside the robust PCA ellipsoids.

(often excluding cytoskeletal proteins) provided highly reliable segmentation of individual cells, even in densely-packed cell islands. This approach enabled us to ‘free’ color channels for labeling cells for additional cellular markers of interest. In addition, the segmentation process allowed us to also calculate the total covered cell area which can report on cell spreading/proliferation/ death during the time of treatment of each of the tested cell lines. Notably, although all lines are of epithelial origin, the RT4 cells (and to some extent HT1376) grow in islands even at low plating density, while TCCSUP and UMUC3 cells grow, primarily as isolated cells, and may be more susceptible to shrinking or contraction. For this reason, the analysis is based primarily on “per-cell” attributes.

The profiling of drug responses based on a single attribute may be misleading, as demonstrated in [Figure 2](#). Dose-response profiles of a single drug (nocodazole) is displayed by eight different attributes (cell area, MT intensity/ area/ texture, actin intensity/ area, nuclei intensity/ area) for two cell lines (TCCSUP, UMUC3). The results are displayed as a “virtual plate”. Various attributes display different responses: tubulin-related attributes in the first four rows indicate the disruption (Blue) of the microtubule network; attributes related to the actin cytoskeleton show little effect after 18 hours; nucleus-related attributes show an

increase (Red) in DNA content per cell, possibly due to cell-cycle arrest.

In order to define an unbiased score that will accumulate drug-induced changes from multi-parametric characterization of cell properties, we have to consider three factors: (1) different attributes have different dimensions and scales; (2) the cell-by-cell variability of each attribute can be quite different; (3) it is not easy to select independent attributes. For example, cell content of a specific detected protein (either by expression of fluorescent derivative or by specific immune-labeling) is highly correlated with cell size. While average protein concentration accounts for this dependency, there are less obvious correlations, reflecting regulated cellular properties, which may become relaxed or tightened in response to drug treatments.

PCA is a well-established method for the characterization of multi-dimensional variability and correlations. We have applied PCA to the quantified attributes in the control wells to best fit a multi-dimensional hyper-ellipsoid, where elongated axes indicate correlated attributes. Using this hyper-ellipsoid, we defined a score based on Mahalanobis distances between each treated cell to the control cells (see Methods and *Extended data: Figure S2*⁵¹). This score balances the scales and variability of the

Figure 2. Different parameters report different response profiles. TCCSUP and UMUC3 cell lines were treated by nocodazole. Image analysis recorded nuclei, cells microtubule and actin-related scores. The response curves clearly depend on the attribute used to quantify the effects, and the strength of the effect depends on the cell line.

measured attributes and accounts for correlations between them. In addition, the hyper-ellipsoid for each of the treated wells provides a multi-parametric scale for identifying outliers, created by technical artifacts such as bubbles, dead cells, cell clumps etc. **Figure 1** shows the multi-parametric Mahalanobis scores for all the COMBO plate drugs applied to the five cell lines tested. The figure compiles 360 Gigabytes of image data (12GB/plate) imaged from 30 multi-well plates. The scores coded in spectral colors are displayed in the plate format that is also used as a “Graphic User Interface” (Plate GUI) showing, upon a mouse-click on a well, montages of the acquired images, outlined cell segments, as well as the full resolution image color components, and a wealth of statistical presentations and cell-by-cell numerical values, facilitating data mining within the large volume of information (see *Extended data*: Figure S1⁵¹).

The scores display differential responses to some of the drugs for some of the cell lines. **Table 1** lists the AC_{50} values obtained for these drugs, as described in the Methods. It should be noted that defined as a “distance”, Mahalanobis scores are always positive. The multi-parametric score is a faithful reporter of changes in any of the measured attributes for all drugs that showed effects. Moreover, once an effect is detected by scoring large Mahalanobis distance to the control ellipsoid, the largest contributions of each of the attributes to the score identify the most significant attribute changes (see examples in **Table 2**). The plate scores for individual high contributors were qualitatively similar (though not identical) to the multi-parametric Mahalanobis scores, yet the latter present in one picture what can only be exhaustively reviewed by many single attribute scores. Altogether, this offers a fast and systematic method with internal

standardization for navigating in multi-dimensional attribute space towards focusing on the cellular phenotype responding to perturbations.

Figure 3 depicts another important feature of cellular responses to drug treatments, namely, time dependence. The effect of drugs with specific molecular target is typically documented using reporter cells displaying target activation. However, the medical value of many drugs often stems from indirect effects. Multi-parametric cell-based measurements can probe both direct and indirect effects. Here the fast disruption of microtubules compared to the slower cell cycle arrest (depicted by DAPI-labeled DNA content) can be seen. Fingerprints of drug effects, based on an array of features or time-dependent of a single feature, suffer from different scales and variabilities of the measured features. The Mahalanobis-scaled fingerprints can include many features at several times, and present more balanced measures for analyses such as multiparametric similarity of drug effects.

In conclusion, multi-parametric analysis of cellular responses to drugs, visualized by high-definition light microscopy screening, allows departing from target-guided drug screening and build essays more sensitive to cell-level functional effects. In addition, since systematic screen of all drug combinations is not practical, selection based on multi-parametric analysis may increase the chance of identifying interactions between different cellular mechanisms favorably affected by drug combinations. In **Figure 4** we show matrices of the responses of one combination (Radicinin and Brasilin) out of 16 binary combinations tested at five 2-fold dilutions around the “ AC_{50} ” concentration of the

Table 2. Mostly contributing attributes. Listed are examples for three drugs, Curcubitacin, Helenalin and Nocodazole, that strongly affected TCCSUP cells as seen in **Figure 1** Plate 1 row 9, plate 3 row 11 and plate 6 row 12 respectively. (A) Curcubitacin-treated TCCSUP indicate rounding up compared to the control cells (Shrinking cells long axis, compare to control cells, the top of **Figure 1**), loss of actin stress fibers (strongly stained condensed actin), and longer, strongly labeled tubulin fibers. (B) Helenalin-treated cells show stronger total per-cell staining of actin & tubulin fibers, and also stronger DAPI staining, compatible with cell cycle arrest. (C) Nocodazole-treated cells indicate loss of tubulin fibers with no disturbance of actin filaments. All the above descriptions based on image visualization are compatible with the three mostly-contributing attributes to the Mahalanobis distance from controls, listed below. Other attributes have normalized Mahalanobis contributions of less than 0.2.

(A) CURCUBITACIN Attribute by order of contribution to Score			
Att. Name:	Cell_LongAxis	Tub_Fib Len	Act_Fib CellInt-Bck
Norm.Contr.Maha:	0.648291	0.347245	0.324186
(B) HELENALIN Attribute by order of contribution to Score			
Att. Name:	Tub AvgInt-Bck	Act CellInt-Bck	Nuc TotInt
Norm.Contr.Maha:	0.572778	0.521640	0.505878
(C) NOCODAZOLE Attribute by order of contribution to Score			
Att. Name:	Tub TotInt-Bck	Tub CellInt-Bck	Tub Len
Norm.Contr.Maha:	0.581077	0.430987	0.319133

Figure 3. Comparison of short and long-term drug effects on attributes. Three plates were treated with 6 drugs for 3 times: 1, 5 & 18h (shown only Nocodazole for 2 cell lines for several attributes). The “virtual plate” displays in rows the different attributes evaluating cellular effects at different time points. Time-response fingerprinting based on a single attribute depends on the attribute chosen, and is not reliably reporting time-dependence of effects. For example, fast (minutes) disruption of microtubules, indirect effects on the actin filaments (an hour), changes in cell spreading, slower cell-cycle arrest (many hours) and cell death (days) are only reported by several time points.

Figure 4. Drug combination essays. The combinations were selected from 20 “responsive” drugs (Table 1). 16 two-drug combination matrices were applied to two cell lines (TCCSUP & UMUC3). 5x5 matrices (10x5 wells including duplicates) + single-drug rows and columns + controls were prepared. 4 dual combinations were set in each plate, 8 plates total (4 for each cell line). Example of 7 single features response for the combination of Radicinin (rows) and Brasilin (columns) in concentrations of 4-0.25μM are displayed for the two cell lines (TOP). The data require preparation of larger matrices with more dilutions and repeats. Nevertheless we attempted to fit the Mahalanobis scores (BOTTOM) to Loewe or Bliss models (see Methods) but found no significant synergism.

single drug treatments. Differences between the two treated cell lines are seen for nuclear-related features. However, Loewe or Bliss model fitting to the Mahalanobis scores does not indicate synergism.

Discussion

Images recording cell, nuclear and cytoskeleton structures were analyzed for five cell lines treated with the COMBO drug library and revealed differential responses. Cell morphology and tagged protein intensity and distribution attributes depicted cellular responses as reported by various features. The transition with time from direct and specific effects on the drug target to indirect and distributed responses manifest the advantages of high-resolution imaging for characterization of cell-level responses by multi-parametric scores. Identification of the features mostly affected by each treatment help guide to relevant cellular functions mediating these responses.

Both basic biological research and biomedical challenges need high-throughput technologies to address the complexity of cellular mechanisms. The information-content in high-throughput experiments, initially confined to biochemical assays reporting a specific target protein, is extending to detailed quantitative sub-cellular characterization, classically the basis for understanding cellular functions. This work developed analysis for high-resolution (recording cytoskeletal fibers) multi-color cellular images from large-scale screens, and display of the results in a digestible form with cell-informatics mining capability. Multi-parametric quantification of cellular effects offers a method to identify cellular responses to drugs without selecting in advance a specific drug targets as a reporter. Effective AC_{50} obtained from multi-parametric analysis integrate many cell-level responses and is therefore less assay-biased than measurements based on single-attribute analysis. Scores based on Mahalanobis distance offer standardized measures of responses in comparison to controls.

Perturbations to living systems, even when the treatment is directed towards a highly specific target with well-defined short-term effects, cause at longer times distributed cellular responses. Characterization of the time-dependence of the direct and indirect responses to drugs using multi-parametric analysis contain causal information to help dissect mechanisms, and may provide rational basis for optimization of temporal schedules for drug administration, already recognized valuable in chemotherapy⁵¹.

Multi-component drug combinations are commonly used in chemotherapy, AIDS and also in antibiotic treatments to fight development of resistant bacteria clones. The effectiveness of such cocktails is often a result of interactions at the physiological level, and was optimized through slow clinical trials. Redundancies and multi-functionalities in molecular networks mediating cellular mechanisms⁶⁰⁻⁶² and the multi-genetic nature of diseases such as cancer, with abnormal protein interactions and modified cellular mechanisms, suggest a potential for the discovery and optimization of multiple-perturbation approaches using cell preparations. Many classical drug targets are shared by the disease phenotypes and the normal ones, causing undesired side effects at the potent doses. Multiple-drug treatments offer degrees of freedom to optimize synergistic interference with a specific

mechanism, preferably more effective in the diseased version and in a given cell lineage, with reduced side effects due to lower doses of each individual drugs in the mixture and minimize compensation by alternative pathways. The benefits of compounds with lower affinity and multiple targets is therefore re-evaluated due to their potential in combinatorial therapies⁶³⁻⁶⁷.

The advancement in our understanding of the molecular mechanisms of cellular functions serves as a basis for rational design of drugs. Combinatorial drug effect profiling is in fact a tool to probe normal network structures⁶⁰⁻⁶². However, first principles quantitative modeling of complex cellular networks depends on many and not readily measurable parameters. Cell-based high-content drug response profiling is therefore a practical method to study multiple perturbations, and to optimize mixtures with advantageous responses. Cell-based assays also open possibilities for patient-specific profiling of abnormal pathways and personal optimization of treatments.

Data availability

Underlying data

The raw data includes 10 Terabytes of images and are therefore too large to share. The images are kept on storage disks as OME-TIFF files with .xml headers metadata for each image. Individuals wishing to access this data can apply to the corresponding author in order to obtain the files. In this situation, these files will be uploaded to and available from the Weizmann Institute of Science website. Example images for one plate are provided in the *Extended data*⁶⁷.

Extended data

Figshare: Multi-parametric characterization of drug effects on cells, <https://doi.org/10.6084/m9.figshare.12981518.v1>⁵⁵.

This project contains the following extended data:

- Table S1. The order of transfer from the COMBO 96-well plates and the COMBO plate handout.
- Table S2. The list of attributes calculated for each cell.
- Figure S1. Analysis Flow Diagram.
- Figure S2. Mahalanobis distance score.

Figshare: Multi-parametric characterization... Original Data, <https://doi.org/10.6084/m9.figshare.12981875.v1>⁵⁵.

- Analysis scripts
- Example images for one plate
- Analyzed data for the example images (Excel file)

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

We thank the NCI for supplying the Combo drugs plate. Pierre Choukroun built our computer grid, and helped us continuously to develop and maintain our computation environment.

References

1. Zeggini E, Gloy AL, Barton AC, *et al.*: **Translational genomics and precision medicine: Moving from the lab to the clinic.** *Science*. 2019; **365**(6460): 1409–1413.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Goto T: **Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine.** *J Pers Med*. 2020; **10**(3): E64.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Ku SY, Gleave ME, Beltran H: **Towards precision oncology in advanced prostate cancer.** *Nat Rev Urol*. 2019; **16**(11): 645–654.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Goutsouliak K, Veeraraghavan J, Sethunath V, *et al.*: **Towards personalized treatment for early stage HER2-positive breast cancer.** *Nat Rev Clin Oncol*. 2020; ; **17**(4): 233–250.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Ho D, Quake SR, McCabe ERB, *et al.*: **Enabling Technologies for Personalized and Precision Medicine.** *Trends Biotechnol*. 2020; **38**(5): 497–518.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Yadav A, Vidal M, Luck K: **Precision medicine - networks to the rescue.** *Curr Opin Biotechnol*. 2020; **63**: 177–189.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Tsimberidou AM, Fountzilas E, Nikanjam M, *et al.*: **Review of precision cancer medicine: Evolution of the treatment paradigm.** *Cancer Treat Rev*. 2020; **86**: 102019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Gambardella V, Tarazona N, Cejalvo JM, *et al.*: **Personalized Medicine: Recent Progress in Cancer Therapy.** *Cancers (Basel)*. 2020; **12**(4): 1009.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Jariyal H, Weinberg F, Achreja A, *et al.*: **Synthetic lethality: a step forward for personalized medicine in cancer.** *Drug Discov Today*. 2020; **25**(2): 305–320.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Hey SP, Gerlach CV, Dunlap G, *et al.*: **The evidence landscape in precision medicine.** *Sci Transl Med*. 2020; **12**(540): eaav7745.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Martorell-Marugán J, Tabik S, Benhammou Y, *et al.*: **Deep Learning in Omics Data Analysis and Precision Medicine.** In: Husi H, editor. *Computational Biology [Internet]*. Brisbane (AU): Codon Publications; 2019; Chapter 3.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Diaz-Ortiz ME, Chen-Plotkin AS: **Omics in Neurodegenerative Disease: Hope or Hype?** *Trends Genet*. 2020; **36**(3): 152–159.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Boufraquech M, Nilubol N: **Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.** *Cancers (Basel)*. 2019; **11**(12): 1988.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Dugourd A, Saez-Rodriguez J: **Footprint-based functional analysis of multiomic data.** *Curr Opin Syst Biol*. 2019; **15**: 82–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Ye Y, Zhang Z, Liu Y, *et al.*: **Multi-omic signatures identify pan-cancer classes of tumors beyond tissue of origin. A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine.** *Trends Genet*. 2020; **36**(5): 318–336.
16. Chen B, Garmire L, Calvisi DF, *et al.*: **Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.** *Nat Rev Gastroenterol Hepatol*. 2020; **17**(4): 238–251.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Haussler J, Alon U: **Tumour heterogeneity and the evolutionary trade-offs of cancer.** *Nat Rev Cancer*. 2020; **20**(4): 247–257.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Bonin S, Stanta G: **Pre-analytics and tumor heterogeneity.** *N Biotechnol*. 2020; **55**: 30–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Marusyk A, Janiszewska M, Polyak K: **Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.** *Cancer Cell*. 2020; **37**(4): 471–484.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Vessoni AT, Filippi-Chiela EC, Lenz G, *et al.*: **Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence.** *Oncogene*. 2020; **39**(10): 2055–2068.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Senosain MF, Massion PP: **Intratumor Heterogeneity in Early Lung Adenocarcinoma.** *Front Oncol*. 2020; **10**: 349.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Scherer F: **Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.** *Recent Results Cancer Res*. 2020; **215**: 213–230.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Janiszewska M: **The microcosmos of intratumor heterogeneity: the space-time of cancer evolution.** *Oncogene*. 2020; **39**(10): 2031–2039.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Kutasovic JR, McCart Reed AE, Sokolova A, *et al.*: **Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer.** *Cancers (Basel)*. 2020; **12**(4): 848.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Parker TM, Henriques V, Beltran A, *et al.*: **Cell competition and tumor heterogeneity.** *Semin Cancer Biol*. 2020; **63**: 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Dagogo-Jack I, Shaw AT: **Tumour heterogeneity and resistance to cancer therapies.** *Nat Rev Clin Oncol*. 2018; **15**(2): 81–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Ma X, Liu J, Zhu W, *et al.*: **3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.** *Adv Drug Deliv Rev*. 2018; **132**: 235–251.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Puls TJ, Tan X, Husain M, *et al.*: **Development of a Novel 3D Tumor-tissue Invasion Model for High-throughput, High-content Phenotypic Drug Screening.** *SCiEntific RePorTS*. 2018; **8**: 13039.
[Publisher Full Text](#)
29. Hou S, Tiriac H, Sridharan BP, *et al.*: **Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.** *SLAS Discov*. 2018; **23**(6): 574–584.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Czerniecki SM, Cruz NM, Harder JL, *et al.*: **High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping.** *Cell Stem Cell*. 2018; **22**(6): 929–940.e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Damiani S, Kompella UB, Damiani SA, *et al.*: **Microfluidic Devices for Drug Delivery Systems and Drug Screening.** *Genes (Basel)*. 2018; **9**(2): 103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Esch EW, Bahinski A, Huh D: **Organs-on-chips at the frontiers of drug discovery.** *Nat Rev Drug Discov*. 2015; **14**(4): 248–260.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Snijder B, Vladimer GI, Krall N, *et al.*: **Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.** *Lancet Haematol*. 2017; **4**(12): e595–e606.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Perez OD, Mitchell D, Campos R, *et al.*: **Multiparameter analysis of intracellular phosphopeptides in immunophenotyped cell populations by flow cytometry.** *Curr Protoc Cytom*. 2005; **Chapter 6**: Unit6.20.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Perlman ZE, Slack MD, Feng Y, *et al.*: **Multidimensional drug profiling by automated microscopy.** *Science*. 2004; **306**(5699): 1194–1198.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Perlman ZE, Mitchison TJ, Mayer TU: **High-content screening and profiling of drug activity in an automated centrosome-duplication assay.** *Chembiochem*. 2005; **6**(1): 145–151.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Conrad C, Erfle H, Warnat P, *et al.*: **Automatic identification of subcellular phenotypes on human cell arrays.** *Genome Res*. 2004; **14**(6): 1130–1136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Huang K, Murphey RF: **From quantitative microscopy to automated image understanding.** *J Biomed Opt*. 2004; **9**(5): 893–912.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Kiger AA, Baum B, Jones S, *et al.*: **A functional genomic analysis of cell morphology using RNA interference.** *J Biol*. 2003; **2**(4): 27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Fraser AG, Kamath RS, Zipperlen P, *et al.*: **Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference.** *Nature*. 2000; **408**(6810): 325–330.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Huh WK, Falvo JV, Gerke LC, *et al.*: **Global analysis of protein localization in budding yeast.** *Nature*. 2003; **425**(6959): 686–691.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Neumann B, Walter T, Hériché JK, *et al.*: **Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes.** *Nature*. 2011; **464**(7289): 721–727.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Conrad C, Wünsche A, Tan TH, *et al.*: **MicroPilot: automation of fluorescence microscopy-based imaging for systems biology.** *Nat Methods*. 2011; **8**(3): 246–249.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Tanaka M, Bateman R, Rauh D, *et al.*: **An unbiased cell morphology-based screen for new, biologically active small molecules.** *PLoS Biol*. 2005; **3**(5): e128.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Melnick JS, Janes J, Kim S, *et al.*: **An efficient rapid system for profiling the cellular activities of molecular libraries.** *Proc Natl Acad Sci U S A*. 2006; **103**(9): 3153–3158.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

46. Pegoraro G, Misteli T: **High-Throughput Imaging for the Discovery of Cellular Mechanisms of Disease.** *Trends Genet.* 2017; **33**(9): 604–615.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Paddison PJ, Silva JM, Conklin DS, *et al.*: **A resource for large-scale RNA-interference-based screens in mammals.** *Nature.* 2004; **428**(6981): 427–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. <https://dtp.cancer.gov/dtpstandard/servlet/PlateMap?searchlist=3948&outputformat=html&searchtype=plate&Submit=Submit>
49. Reuter VE: **The pathology of bladder cancer.** *Urology.* 2006; **67**(3 Suppl): 11–7; discussion 17–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Farkash-Amar S, Eden E, Cohen A, *et al.*: **Dynamic proteomics of human protein level and localization across the cell cycle.** *PLoS One.* 2012; **7**(11): e48722.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Kam Z, Geiger B, Paran Y, *et al.*: **Multi-parametric characterization of drug effects on cells.** *figshare.* Figure. 2020.
<http://www.doi.org/10.6084/m9.figshare.12981518.v1>
52. Liron Y, Paran Y, Zatorsky NG, *et al.*: **Laser autofocus system for high-resolution cell biological imaging.** *J Microsc.* 2006; **221**(Pt 2): 145–151.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Paran Y, Lavelin I, Naffar-Abu-Amara S, *et al.*: **Development and application of automatic high-resolution light microscopy for cell-based screens.** *Methods Enzymol.* 2006; **414**: 228–247.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Paran Y, Ilan M, Kashman Y, *et al.*: **High-throughput screening of cellular features using high-resolution light-microscopy; application for profiling drug effects on cell adhesion.** *J Struct Biol.* 2007; **158**(2): 233–243.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Kam Z: **Multi-parametric characterization... Original Data.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12981875.v1>
56. Chou TC, Talalay P: **A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.** *J Biol Chem.* 1977; **252**(18): 6438–6442.
[PubMed Abstract](#)
57. Chou TC: **Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands.** *J Theor Biol.* 1976; **59**(2): 253–276.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Chou TC: **On the determination of availability of ligand binding sites in steady-state systems.** *J Theor Biol.* 1977; **65**(2): 345–356.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Wu J, Waxman DJ: **Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.** *Cancer Lett.* 2018; **419**: 210–221.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Keith CT, Borisy AA, Stockwell BR: **Multicomponent therapeutics for networked systems.** *Nat Rev Drug Discov.* 2005; **4**(1): 71–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Yeh P, Tschumi AI, Kishony R: **Functional classification of drugs by properties of their pairwise interactions.** *Nat Genet.* 2006; **38**(4): 489–494.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Yeh P, Kishony R: **Networks from drug-drug surfaces.** *Mol Syst Biol.* 2007; **3**: 85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Fitzgerald JB, Schoeberl B, Nielsen UB, *et al.*: **Systems biology and combination therapy in the quest for clinical efficacy.** *Nat Chem Biol.* 2006; **2**(9): 458–466.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Lee MS, Johansen L, Zhang Y, *et al.*: **The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action.** *Cancer Res.* 2007; **67**(23): 11359–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Lehár J, Krueger A, Zimmermann G, *et al.*: **High-order combination effects and biological robustness.** *Mol Syst Biol.* 2008; **4**: 215.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Verissimo CS, Overmeer RM, Ponsioen B, *et al.*: **Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.** *eLife.* 2016; **5**: e18489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Pemovska T, Bigenzahn JW, Superti-Furga G: **Recent advances in combinatorial drug screening and synergy scoring.** *Curr Opin Pharmacol.* 2018; **42**: 102–110.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 14 December 2020

<https://doi.org/10.5256/f1000research.28977.r75113>

© 2020 Murphy R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Robert Murphy

Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, USA

This manuscript describes high throughput microscopy measurement and analysis of the effects of drugs using multiple fluorescent probes. While the study has been carefully done and the results for particular drugs may be of interest to researchers, the manuscript does not represent a significant advance either in experimental approach or in subsequent analysis. The use of multiple simultaneous fluorescent probes is widespread in biomedical research, including in drug development. For example, the work on cell painting described by Bray *et al.* is has been widely cited and used.¹ The use of similar multivariate statistical methods for analysis of the signals from those probes is also routine.

References

1. Bray MA, Singh S, Han H, Davis CT, et al.: Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. *Nat Protoc.* **11** (9): 1757-74 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Yes

Are sufficient details provided to allow replication of the method development and its use by others?

Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: computational cell biology, biological image analysis and modeling

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 19 Dec 2020

Zvi Kam, Weizmann Institute of Science, Rehovot, Israel

We believe that the ability to detect drug effects on cells and relate them, in an unbiased fashion to quantitative attributes extracted from the images is a key feature that is missing when screens are directed towards identification of drugs or genes related to predetermined functional or morphological effects. The unbiased approach provided by Mahalanobis score and the identification of "most contributing attributes" to score differences from controls may reveal unexpected results in laborious screen preparations, independently of the initial aims of the work.

Competing Interests: no competing interests

Reviewer Report 26 October 2020

<https://doi.org/10.5256/f1000research.28977.r72645>

© 2020 Lock J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

John Lock

School of Medical Sciences, University of New South Wales, Sydney, Australia

This article delineates a novel strategy and accompanying analytical platform to assess and compare the complex, multiparametric effects of drug treatments on cell populations (at the single cell level). The platform, described in detail, couples cell phenotype (fluorescence) imaging and an integrated quantitative image analysis and statistical data analysis/visualisation capability that enable rapid exploration of cellular states/responses across multiple scales of the data hierarchy.

Focused on data capturing the level of single cell phenotypes measured through imaging with

subcellular resolution, this article captures an analytical strategy that is relevant to drug discovery, but also to fundamental analysis of cellular processes, their underlying mechanisms, and potentially, diagnostic assessment/identification of defective processes in disease states.

Using the NCI COMBO drug library as a basis for analysis, the authors detail the experimental, imaging, and image analysis process, but reserve particular focus for the methods of drug effect analysis, primarily relying on the Mahalanobis distance. This measure captures a compact representation of drug effect strengths relative to control variation, whilst also embedding information about the (relative weights) of specific cellular features that capture/comprise the effects of any given perturbation (drug). Mahalanobis distance thus emerges as a powerful tool to assess, compare, sort, and visualise drug effects, especially when compared (as the authors show) with single feature responses, which are far less systematic in their indications.

The authors also highlight the strengths of their approach for identifying complex temporal dynamics of drug response, i.e. how changes in different phenotypic features emerge at different times after treatment. Reflecting the way that even highly specific initial perturbation impacts are propagated outward over time within cellular information processing and responses networks, this is an important additional dimension that is precisely addressed using the authors' analytical strategy.

Importantly, due to the very large scale of the datasets described, the authors indicate (reasonably so) that it is not feasible to share the entire dataset online. However, they indicate that, on request, components, or the entirety of the dataset can be accessed based on a request to the corresponding author. I interpret this as constituting data availability *in practice*.

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Yes

Are sufficient details provided to allow replication of the method development and its use by others?

Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Systems Microscopy of cancer cell biology, including signalling, cytoskeletal

regulation, adhesion and migration biology. Phenotypic drug screening. Development of image analysis, statistical analysis, and data visualisation tools for quantitative single cell analysis based on imaging data.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research